Scarica l'app Stockscreener
40.15
1.71%
-0.70
Pre-mercato:
40.50
0.35
+0.87%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALKS Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$40.85
Aprire:
$40.71
Volume 24 ore:
2.09M
Relative Volume:
1.10
Capitalizzazione di mercato:
$6.74B
Reddito:
$1.56B
Utile/perdita netta:
$152.72M
Rapporto P/E:
44.64
EPS:
0.8994
Flusso di cassa netto:
$221.80M
1 W Prestazione:
-9.12%
1M Prestazione:
-15.31%
6M Prestazione:
+36.61%
1 anno Prestazione:
+43.96%
Intervallo 1D:
$40.04
$40.97
Intervallo di 1 settimana:
$40.04
$44.53
Portata 52W:
$27.00
$55.67
Alkermes Plc Stock (ALKS) Company Profile
Nome
Alkermes Plc
Settore
Telefono
00-353-1-772-8000
Indirizzo
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS vs TAK, TEVA, HLN, ZTS, VTRS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
40.15 | 6.85B | 1.56B | 152.72M | 221.80M | 0.8994 |
TAK
Takeda Pharmaceutical Co Adr
|
18.90 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
38.88 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.43 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
VTRS
Viatris Inc
|
18.27 | 20.48B | 14.57B | -296.50M | 1.64B | -0.259 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-06-29 | Downgrade | BofA Securities | Neutral → Underperform |
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2025-11-11 | Iniziato | Truist | Buy |
| 2025-09-26 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | Iniziato | Wells Fargo | Overweight |
| 2025-07-15 | Iniziato | Goldman | Buy |
| 2025-06-17 | Aggiornamento | UBS | Neutral → Buy |
| 2025-05-28 | Iniziato | Needham | Buy |
| 2025-03-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | Aggiornamento | UBS | Sell → Neutral |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-11-05 | Aggiornamento | Stifel | Hold → Buy |
| 2024-06-17 | Iniziato | TD Cowen | Buy |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-20 | Downgrade | UBS | Neutral → Sell |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-10-24 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Iniziato | UBS | Neutral |
| 2022-11-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Iniziato | Piper Sandler | Neutral |
| 2022-04-22 | Ripresa | Goldman | Buy |
| 2022-04-20 | Iniziato | Goldman | Buy |
| 2022-01-27 | Aggiornamento | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Iniziato | Citigroup | Neutral |
| 2021-10-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-09-02 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-07-30 | Downgrade | Goldman | Neutral → Sell |
| 2020-02-14 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Reiterato | H.C. Wainwright | Neutral |
| 2020-02-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-01-31 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-05-31 | Iniziato | H.C. Wainwright | Neutral |
| 2019-05-01 | Downgrade | Citigroup | Buy → Neutral |
| 2018-12-19 | Downgrade | Goldman | Neutral → Sell |
| 2018-12-14 | Iniziato | Wolfe Research | Underperform |
| 2018-12-13 | Downgrade | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Iniziato | Piper Jaffray | Neutral |
| 2018-08-07 | Iniziato | Stifel | Hold |
| 2018-06-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Alkermes Plc Borsa (ALKS) Ultime notizie
Alkermes plc Hired Firms, 2023 - OpenSecrets
Alkermes plc Hired Firms, 2011 - OpenSecrets
Alkermes: Idiopathic Hypersomnia Could Expand LUMRYZ Into A Larger Growth, Margin Driver - Seeking Alpha
Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works? - Insider Monkey
Alkermes Must Face Bulk Of Addiction Treatment Drug Suit - Law360
Alkermes Fails to Fend Off Addiction Treatment Antitrust Claim - Bloomberg Law News
Alkermes plc (AKD.DE) Analyst Insights, Price Targets & RecommendationsYahoo Finance - Yahoo! Finance Canada
Alkermes PLC (ALKS) Shares Fall 3.2% -- GF Value Says Still Over - GuruFocus
ALKS Reinstated by Goldman Sachs -- Rating Set to Neutral - GuruFocus
Alkermes plc (ALKS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Goldman Sachs resumes Alkermes stock coverage with neutral rating - Investing.com
ALKS Looks 29.1% Overvalued on GF Value™ - GuruFocus
Alkermes Says Experimental Drug Could Open New Path in ADHD Treatment - Yahoo
Alkermes: The Orexin Upside Is Real, But Takeda And Lilly Stand In The Way (Downgrade) - Seeking Alpha
Why Alkermes (ALKS) Is Down 6.0% After First ADHD Data For Orexin Agonist ALKS 7290 - Yahoo Finance
Annual Research Grant Program Expands Focus to Include Narcolepsy - Sleep Review
ALKS News | ALKERMES PLC (NASDAQ:ALKS) - ChartMill
ALKS Reiterated by RBC Capital -- Price Target Maintained at $56 - GuruFocus
ALKS Maintains by Baird -- Price Target Raised to $61.00 - GuruFocus
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290 - finance.yahoo.com
Alkermes reports positive top-line Phase Ib trial data for ALKS 7290 - Clinical Trials Arena
TD Cowen reiterates Alkermes stock Buy rating on ADHD trial data - Investing.com Australia
Form 8K Alkermes plc. For: 21 September By Investing.com - Investing.com Nigeria
Alkermes Shares Jump 6.5% After ADHD Drug Shows Clinical Proof-of-Concept - finance.biggo.com
ALKS Looks 34.7% Overvalued on GF Value™ - GuruFocus
Alkermes' ALKS7290 shows strong early results i... - Pluang
ALKS Reiterates by Needham -- Price Target Maintained at $62.00 - GuruFocus
Alkermes Announces Positive Phase 1 Topline Results for ALKS 7290 in ADHD Treatment - Kalkine Media
Stifel reiterates Alkermes stock rating on ADHD drug trial data By Investing.com - Investing.com Australia
Alkermes reports positive phase 1 data for ADHD drug candidate By Investing.com - Investing.com Australia
ALKS Looks 33.1% Overvalued on GF Value™ as ADHD Drug Shows Earl - GuruFocus
Alkermes rises on phase 1 results for ADHD drug ALKS 7290 - Seeking Alpha
Alkermes Shares Rise 6.5% After Positive Phase 1b Results for ADHD Drug ALKS 7290 - Yahoo Finance
Why is Alkermes stock surging today? By Investing.com - Investing.com Canada
Alkermes stock jumps on positive ADHD drug trial results - Investing.com
Alkermes reports positive phase 1 data for ADHD drug candidate - Investing.com
Alkermes Announces Positive Phase 1b Results for ALKS 7290 in Adults With ADHD - TradingView
Alkermes plc: Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) - FinanzNachrichten.de
An ADHD drug in testing cut symptom scores by 19 points - Stock Titan
Alkermes Plc (ALKS) Stock Analysis: A Look At Its 29.88% Potential Upside - DirectorsTalk Interviews
ALKS Looks 33.6% Overvalued on GF Value™ as Shares Drop to June Lows - GuruFocus
Alkermes PLC (ALKS) Shares Fall 7.1% -- What GF Score of 64 Tells Investors - GuruFocus
Alkermes Falls as Investors Appear to Take Profits Despite No Obvious Negative Company Update - Quiver Quantitative
Anne Clem Whitaker is director at Alkermes (NASDAQ: ALKS) with no reported holdings - Stock Titan
Alkermes slides 7%, reaching multi-month low (ALKS:NASDAQ) - Seeking Alpha
Alkermes Strengthens Board with New Director Appointment - The Globe and Mail
REGBlackRock GroupSAR 6ALKERMES PLC - TradingView
Form 8K Alkermes plc. For: 16 September By Investing.com - Investing.com Nigeria
Alkermes Expands Board with Anne C. Whitaker Appointment and Details Compensation Package - Kalkine Media
Alkermes Appoints Anne C. Whitaker to Board of Directors - citybiz
New Alkermes (NASDAQ: ALKS) director to get $600,000 in stock awards - Stock Titan
Alkermes Plc Azioni (ALKS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):